Haisco Pharmaceutical Group revenue and financials
¥62.18Change from previous close: +0.40%Absolute change: +¥0.25
In the fiscal year ended December 2025, Haisco Pharmaceutical Group reported revenue of ¥4.39B (+17.91% year over year). Net income was ¥259.58M, a net margin of 5.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +17.91%
- 2025 vs 2024
- Net income growth
- −34.36%
- 2025 vs 2024
- Net margin
- 5.9%
- 2024: 10.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total revenue | 1,532 | 1,564 | 1,088 | 1,109 | 892 |
| Cost of revenue | 321 | 291 | 404 | 276 | 265 |
| Gross profit | 1,211 | 1,273 | 684 | 833 | 627 |
| Selling, general and administrative | 72.1 | 473 | -251 | 47.8 | 412 |
| Research and development | 353 | 225 | 262 | 199 | 143 |
| Operating income | 330 | 601 | -59.5 | 114 | 78.5 |
| EBIT | 287 | 600 | -56.5 | 97.8 | 66.9 |
| EBITDA | 287 | 600 | -56.5 | 97.8 | 66.9 |
| Interest expense | 7.1 | 6.8 | 7.6 | 8.3 | 8.5 |
| Pre-tax income | 280 | 593 | -64.1 | 89.5 | 58.4 |
| Income tax | -16.6 | 38.3 | -28.4 | 7.3 | 11.8 |
| Net income | 297 | 555 | -35.7 | 82.2 | 46.6 |
| Net income to common shareholders | 297 | 555 | -35.7 | 82.2 | 46.6 |
| Basic EPS | — | 0.50 | — | — | 0.04 |
| Diluted EPS | — | 0.50 | — | — | 0.04 |
| Average shares (basic) | — | 1,109 | — | — | 1,165 |
| Average shares (diluted) | — | 1,109 | — | — | 1,165 |